Developing cellular immunotherapies for cancers and orphan inherited blood disorders
Bellicum Pharmaceuticals is focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The company is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing potential next-generation product candidates in several areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies.
